CCCC - Company ID 0001662579
The table below shows C4 Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.94M | -$33.28M | -$18.12M | -$33.13M | -$26.60M | -$24.93M |
| Capital expenditure | $64.00K | $0.00 | $0.00 | $589.00K | $172.00K | $421.00K |
| Investing cash flow | $16.15M | $29.13M | -$53.40M | $53.53M | -$4.00M | -$61.73M |
| Dividends paid | - | - | - |
C4 Therapeutics, Inc. reported operating cash flow of -$98.69M for fiscal year 2025. That is down 51.5% from -$65.16M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $55.61M (FY 2019) to -$98.69M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | $200.00K | $155.00K | $109.00K | $94.00K | $0.00 | - |
| Financing cash flow | $462.00K | -$46.00K | $34.58M | -$684.00K | $480.00K | -$151.00K |